Norvir-Boosted Protease Regimen Bests Other Regimens
People taking an antiretroviral (ARV) treatment regimen that includes a protease inhibitor (PI) boosted with low-dose Norvir (ritonavir) were less likely to develop drug resistance than people taking other types of regimens, according to the authors of a study published in the July 1 issue of the Journal of Infectious Diseases.
Current federal HIV treatment guidelines recommend regimens containing either a Norvir-boosted PI or a non-nucleoside reverse transcriptase inhibitor (NNRTI) for people starting antiretroviral (ARV) treatment for the first time. If people can’t tolerate a boosted PI or an NNRTI, they may use a PI that isn’t boosted with low-dose Norvir.
To determine which regimens are likely to have the most prolonged benefit—and the least likely to be limited by the development of drug-resistance mutations in HIV—Viviane Lima, PhD, from the British Columbia Centre for Excellence in HIV/AIDS in Vancouver, and her colleagues compared the medical records of a cohort of 2,350 people living with HIV taking NNRTI-, boosted-PI-, or unboosted-PI-based regimens between August 1996 and November 2004.
Un-boosted PIs were most likely to be used in the late 1990s, with people often taking Crixivan (indinavir) or Viracept (nelfinavir). NNRTI use gained popularity around 1999, with many patients initially using Viramune (nevirapine). Boosted PI regimens gained favor beginning in 2002 and most commonly included Kaletra (lopinavir/ritonavir), followed by Reyataz (atazanavir).
Lima’s team found that the development of resistance occurred at the same rate in people who started treatment with an un-boosted PI as in those who started treatment with an NNRTI. However, people who started treatment with a boosted PI were nearly two and a half times less likely to develop drug resistance than people on an NNRTI or an un-boosted PI.
The year treatment was started also made a difference. Those starting treatment after 2002—regardless of the type of treatment regimen—were about 60 percent less likely to develop resistance than people who started treatment before 2002.
NEW! Scroll down to comment on this story.
Please click OK to confirm your comment and confirm you accept our posting rules. Note your message will be reviewed by our staff before going live.
Beth Benne, RN, is HIV negative, but
the virus has impacted her life. She currently supervises a biannual HIV/AIDS awareness week as
the director of the student health center at Pierce College, a
community commuter school in Woodland Hills, California.
Woman of the Month is supported by exclusive advertising from Gilead.
Overheard in the Women's Forum
"I recently met a guy who is negative. I did tell him about my status and he decided to kiss me anyway (we didn't go further than that). But a day later, he called and said that he actually had a mouth ulcer that time when we kissed and he was very worried. Asked if he can get the virus from me that way. For that moment, I felt so insulted and yet I felt so bad. It was my first time having a contact with a "negative" guy."
